Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,666 total articles

XCharge Appoints Albina Iljasov as Co-Chief Executive Officer

XCharge Appoints Albina Iljasov as Co-Chief Executive Officer

XCHG Limited, a Nasdaq-listed integrated EV charging and energy solutions company, appointed Albina Iljasov as Co-Chief Executive Officer effective June 1, 2026. Iljasov will oversee European operations and spearhead information security and cybersecurity efforts, complementing existing Co-CEO Yifei Hou. The move signals XCharge's commitment to glo…

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Iovance Biotherapeutics announced FDA clearance of their investigational new drug (IND) application for IOV-5001, a next-generation interleukin-12 (IL-12) tethered tumor infiltrating lymphocyte (TIL) therapy. The Phase 1/2 trial aims to treat multiple advanced solid tumors including colorectal and breast cancers, with enrollment expected in the sec…

SL Green Announces the Sale of 10 East 53rd Street

SL Green Announces the Sale of 10 East 53rd Street

SL Green Realty Corp., Manhattan's largest office landlord, announced the sale of 10 East 53rd Street to Meadow Partners for $312.2 million. The sale, expected to close in Q3 2026, will generate approximately $100 million in net cash proceeds to reduce corporate debt. This transaction advances SL Green's $2.5 billion strategic disposition plan and …

Anterix Sets Fourth Quarter Fiscal 2026 Earnings Conference Call for Thursday, June 11, at 9:00 a.m. ET

Anterix Sets Fourth Quarter Fiscal 2026 Earnings Conference Call for Thursday, June 11, at 9:00 a.m. ET

Anterix Inc., a leading provider of private wireless broadband spectrum solutions for critical infrastructure, announced its fourth quarter fiscal 2026 earnings conference call will take place on June 11, 2026. The company will discuss its quarterly results following a press release after market close on June 10. Anterix continues to focus on deliv…

Cognition Therapeutics Participating in Upcoming Investor Conferences

Cognition Therapeutics Participating in Upcoming Investor Conferences

Cognition Therapeutics, a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced CEO Lisa Ricciardi will present at two upcoming investor conferences, sharing updates on the company's development plans for its lead drug candidate zervimesine (CT1812), targeting dementia with Lewy bodies (DLB) psychosis. The compan…

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics announced the commercial launch of MYQORZO® (aficamten) in Germany, marking its first European availability for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows FDA approval and market introduction in the U.S. and China. The European Commission approved MYQORZO based on positive Phase 3 clinical trial results de…

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx Corp., a healthcare technology company specializing in AI-driven marketing solutions for life sciences, announced that its management will participate in prominent investor conferences including the Stifel 2026 Boston Cross Sector Conference and the 46th Annual William Blair Growth Stock Conference. The participation aims to showcase the…

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TG Therapeutics announced publication of post-hoc pooled analyses from the Phase 3 ULTIMATE I & II trials demonstrating that BRIUMVI (ublituximab-xiiy) provides significant clinical and MRI improvements versus teriflunomide in treatment-naïve adult patients with relapsing multiple sclerosis (RMS). The data supports early use of this high-efficacy t…

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics announced it will present additional data from its global Phase 3 HAELO trial of lonvo-z, a one-time CRISPR-based gene editing therapy for hereditary angioedema (HAE), at the EAACI 2026 Congress. This late-breaking oral presentation highlights the potential of lonvo-z to become the first permanent treatment to prevent HAE atta…

Athene Announces Key Leadership Appointment

Athene Announces Key Leadership Appointment

Athene, a leading retirement solutions company and subsidiary of Apollo Global Management, appointed Matthew Michelini as President of Athene Holding Ltd., effective July 1, 2026. Michelini brings extensive experience from Apollo, including leadership in Asia-Pacific, and will focus on advancing growth initiatives and reinventing guaranteed lifetim…

Nayax Launches AI-Powered Product Discovery for Retailers

Nayax Launches AI-Powered Product Discovery for Retailers

Nayax Ltd., a global payments and commerce enablement platform, launched a new AI-powered product discovery and personalization feature integrated into its platform. This solution helps retailers utilize real-time shopper data across multiple channels to provide personalized recommendations, thereby increasing customer engagement and sales. The pro…

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Corp. announced positive clinical data from Phase 2 and ongoing Phase 3 studies of its Bria-IMT immunotherapy for heavily pre-treated metastatic breast cancer patients at the 2026 ASCO Annual Meeting. Data demonstrated promising survival rates, good quality of life, and potential predictive biomarkers, supporting continued dev…

New Era Energy & Digital Announces Upcoming Conference Participation and Expected Russell Index Inclusion

New Era Energy & Digital Announces Upcoming Conference Participation and Expected Russell Index Inclusion

New Era Energy & Digital, Inc. announced participation in several major investor and industry conferences in June 2026, highlighting its leadership presence. The company also expects to be added to the Russell 3000 and Russell Microcap Indexes following the annual reconstitution, effective June 29, 2026. This inclusion signals increased visibility …

Edible Garden Accelerates Path to Profitability Through Major Logistics Transformation, Reducing Operating Costs, Lowering Emissions and Enhancing Supply Chain Efficiency

Edible Garden Accelerates Path to Profitability Through Major Logistics Transformation, Reducing Operating Costs, Lowering Emissions and Enhancing Supply Chain Efficiency

Edible Garden AG Incorporated has completed a major logistics overhaul in the Metro New York area, shifting from a Direct Store Delivery model to a direct-to-distribution-center and regional hub model. This change is expected to significantly reduce transportation costs and carbon emissions, improving operational efficiency and supporting the compa…

Piedmont REIT Signs 240,000 SF of Leases Second Quarter-to-Date Bringing YTD Leasing to approximately 670,000 SF

Piedmont REIT Signs 240,000 SF of Leases Second Quarter-to-Date Bringing YTD Leasing to approximately 670,000 SF

Piedmont Realty Trust announced that it has signed approximately 240,000 square feet of leases in the second quarter so far, with more than 60% representing new tenant leasing and 90% of new leases for previously vacant spaces. This brings the year-to-date leasing volume to approximately 670,000 square feet. The company highlights sustained high de…

IREN Closes $3.65bn Investment-Grade GPU Financing

IREN Closes $3.65bn Investment-Grade GPU Financing

IREN Limited has successfully closed a $3.65 billion investment-grade GPU financing facility, the largest publicly rated GPU financing to date, to support its AI Cloud contract with Microsoft. The facility includes a $2.10 billion U.S. private placement and a $1.55 billion delayed draw term loan, funding 96% of the $5.81 billion GPU capital expendi…

SAIC Announces First Quarter of Fiscal Year 2027 Results

SAIC Announces First Quarter of Fiscal Year 2027 Results

Science Applications International Corporation (SAIC) announced its Q1 FY2027 results with revenues of $1.91 billion, a 2% increase including acquisitions, and modest organic growth of 0.5%. The company reported adjusted EBITDA of $222 million, a 41% increase year-over-year, and adjusted diluted EPS of $3.23, up 68%. Cash flow from operations impro…

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Invivyd, Inc., a U.S.-based biopharmaceutical company, announced the completion of enrollment in its Phase 3 DECLARATION clinical trial testing VYD2311, an investigational monoclonal antibody administered intramuscularly for the prevention of symptomatic COVID-19. The trial was upsized by approximately 500 subjects to enhance statistical power due …

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences announced positive interim Phase 1 trial results of JADE101, a novel anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN). Results demonstrated approximately 70% sustained IgA reduction at 12 weeks after a single dose, with potential for every 12-week subcutaneous maintenance dosing. JADE101 showed faster, deeper,…

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 clinical trial results of ALXN1840 at EASL 2026, demonstrating stabilization of liver disease and significant neurological improvements in treatment-experienced Wilson disease patients. The therapy was well tolerated and improved patients' quality of life, highlighting its potential as a novel treatment option…

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Axsome Therapeutics is supporting the Headache Alliance’s first annual Headache in the City campaign and raising awareness during Migraine and Headache Awareness Month. The company highlights the significant impact of migraine and shares educational resources, reinforcing its commitment to the migraine community as part of its broader mission to tr…